Gene therapy applications of non-human lentiviral vectors

Recent commercialization of lentiviral vector (LV)-based cell therapies and successful reports of clinical studies have demonstrated the untapped potential of LVs to treat diseases and benefit patients. LVs hold notable and inherent advantages over other gene transfer agents based on their ability t...

Szczegółowa specyfikacja

Opis bibliograficzny
1. autor: Munis, AM
Format: Journal article
Język:English
Wydane: MDPI 2020
_version_ 1826270432345456640
author Munis, AM
author_facet Munis, AM
author_sort Munis, AM
collection OXFORD
description Recent commercialization of lentiviral vector (LV)-based cell therapies and successful reports of clinical studies have demonstrated the untapped potential of LVs to treat diseases and benefit patients. LVs hold notable and inherent advantages over other gene transfer agents based on their ability to transduce non-dividing cells, permanently transform target cell genome, and allow stable, long-term transgene expression. LV systems based on non-human lentiviruses are attractive alternatives to conventional HIV-1-based LVs due to their lack of pathogenicity in humans. This article reviews non-human lentiviruses and highlights their unique characteristics regarding virology and molecular biology. The LV systems developed based on these lentiviruses, as well as their successes and shortcomings, are also discussed. As the field of gene therapy is advancing rapidly, the use of LVs uncovers further challenges and possibilities. Advances in virology and an improved understanding of lentiviral biology will aid in the creation of recombinant viral vector variants suitable for translational applications from a variety of lentiviruses.
first_indexed 2024-03-06T21:40:44Z
format Journal article
id oxford-uuid:47d586cd-d7b4-454e-b663-d6e7e32cafdb
institution University of Oxford
language English
last_indexed 2024-03-06T21:40:44Z
publishDate 2020
publisher MDPI
record_format dspace
spelling oxford-uuid:47d586cd-d7b4-454e-b663-d6e7e32cafdb2022-03-26T15:22:18ZGene therapy applications of non-human lentiviral vectorsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:47d586cd-d7b4-454e-b663-d6e7e32cafdbEnglishSymplectic ElementsMDPI2020Munis, AMRecent commercialization of lentiviral vector (LV)-based cell therapies and successful reports of clinical studies have demonstrated the untapped potential of LVs to treat diseases and benefit patients. LVs hold notable and inherent advantages over other gene transfer agents based on their ability to transduce non-dividing cells, permanently transform target cell genome, and allow stable, long-term transgene expression. LV systems based on non-human lentiviruses are attractive alternatives to conventional HIV-1-based LVs due to their lack of pathogenicity in humans. This article reviews non-human lentiviruses and highlights their unique characteristics regarding virology and molecular biology. The LV systems developed based on these lentiviruses, as well as their successes and shortcomings, are also discussed. As the field of gene therapy is advancing rapidly, the use of LVs uncovers further challenges and possibilities. Advances in virology and an improved understanding of lentiviral biology will aid in the creation of recombinant viral vector variants suitable for translational applications from a variety of lentiviruses.
spellingShingle Munis, AM
Gene therapy applications of non-human lentiviral vectors
title Gene therapy applications of non-human lentiviral vectors
title_full Gene therapy applications of non-human lentiviral vectors
title_fullStr Gene therapy applications of non-human lentiviral vectors
title_full_unstemmed Gene therapy applications of non-human lentiviral vectors
title_short Gene therapy applications of non-human lentiviral vectors
title_sort gene therapy applications of non human lentiviral vectors
work_keys_str_mv AT munisam genetherapyapplicationsofnonhumanlentiviralvectors